PhaseRx (PZRX) Getting Somewhat Favorable Press Coverage, Analysis Finds

Media coverage about PhaseRx (NASDAQ:PZRX) has been trending somewhat positive this week, according to Accern Sentiment. The research group ranks the sentiment of news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. PhaseRx earned a media sentiment score of 0.10 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 44.9945695380549 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

PhaseRx (NASDAQ PZRX) opened at $1.00 on Monday. The company has a quick ratio of 2.14, a current ratio of 2.14 and a debt-to-equity ratio of -12.03. PhaseRx has a 1 year low of $0.54 and a 1 year high of $1.95.

PhaseRx (NASDAQ:PZRX) last posted its earnings results on Thursday, November 9th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.37) by $0.14.

Separately, Laidlaw downgraded PhaseRx from a “buy” rating to a “neutral” rating in a research report on Friday, October 13th.

TRADEMARK VIOLATION WARNING: “PhaseRx (PZRX) Getting Somewhat Favorable Press Coverage, Analysis Finds” was posted by Community Financial News and is the property of of Community Financial News. If you are reading this report on another website, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this report can be read at https://www.com-unik.info/2017/12/11/phaserx-pzrx-getting-somewhat-favorable-press-coverage-analysis-finds.html.

About PhaseRx

PhaseRx, Inc is a biopharmaceutical company developing a portfolio of mRNA products to correct life-threatening inherited liver diseases in children. The Company’s initial product development focus is on urea cycle disorders, a group of rare genetic diseases that generally present before the age of 12 and are characterized by the body’s inability to remove ammonia from the blood.

Insider Buying and Selling by Quarter for PhaseRx (NASDAQ:PZRX)

What are top analysts saying about PhaseRx Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for PhaseRx Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit